PremiumThe FlyMarker Therapeutics initiated with a Buy at Canaccord Marker Therapeutics Grants Stock Options to Directors Marker Therapeutics initiated with a Buy at Brookline PremiumThe FlyMarker Therapeutics awarded $9.5M grant from CPRIT Marker Therapeutics files $300M mixed securities shelf Marker Therapeutics Advances in Clinical Trials and Finances PremiumCompany AnnouncementsMarker Therapeutics’ Promising Cancer Therapy Progress Marker Therapeutics initiated with a Buy at Ladenburg on post-CAR-T opportunity Marker Therapeutics initiated with a Buy at Ladenburg